Collaborating with outstanding researchers, academic institutions, entrepreneurs and leaders in the biotech and pharma industry, we provide capital, network and know-how to transform promising life-science discoveries into successful biotech startups.
Covering the spectrum from early-stage discoveries to clinical-stage companies, we focus on two main areas:
- Company creation and building biotech startups in the Nordic region.
- Early-stage investments in promising biotech and medtech companies in the rest of Europe.
Building on our curiosity, network, determination and long-term perspective, we aim to develop strong and competitive companies. We finance successful companies all the way to a commercial exit.
With this platform, we strive to be the preferred early-stage investor and partner of the European life science industry.
In 2016, we invested about DKK 150 million in new companies, and we currently have 18 active portfolio companies. In the coming years, we will continue to increase our investments activities in both the Nordics and other parts of Europe.